Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome

Ya Ru Zhang, Zheng Kai Xue, Kang Yin Chen, Ling Xia Xu, Wei Ding Wang, Hua Yue Tao, Tong Liu, Jing Jin Che, Xue Wen Wang, Seung Woon Rha, Jia Rui Wang, Peng Wang

Research output: Contribution to journalArticle

Abstract

Background: Periprocedural myocardial infarction is a common complication following percutaneous coronary intervention. The present study was conducted with an aim to compare the safety and efficacy of loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Methods: A total of 114 patients with acute coronary syndrome undergoing elective percutaneous coronary intervention were assigned to clopidogrel group (n = 57, the loading and maintenance doses were 300 and 75 mg qd for clopidogrel, and 300 and 100 mg qd for aspirin), or ticagrelor group (n = 57, the loading and maintenance doses were 180 and 90 mg bid for ticagrelor, and 300 and 100 mg qd for aspirin). Cardiac biomarkers were measured before, 8 hours, and 24 hours after percutaneous coronary intervention. The percutaneous coronary intervention–related periprocedural myocardial infarction was defined according to the fourth universal definition of myocardial infarction (2018). Results: The overall incidence of percutaneous coronary intervention–related periprocedural myocardial infarction was 21.1%. The ticagrelor group showed a significantly lower incidence of periprocedural myocardial infarction (12.3% vs 29.8%, p = 0.022) and numerically lower bleeding events (3.5% vs 8.8%, p = 0.242) as compared with clopidogrel group. No patient had major adverse cardiovascular events during the 1-month follow-up. The levels of high-sensitivity C-reactive protein did not differ significantly between the two groups (p > 0.05), indicating that the benefits of ticagrelor were not from its anti-inflammatory effects. Multivariable analysis showed that the use of ticagrelor (odds ratio: 0.50; 95% confidence interval: 0.29-0.87; p = 0.014) and number of stents (odds ratio: 2.75; 95% confidence interval: 1.25-6.06; p = 0.012) were independent predictors of periprocedural myocardial infarction. Conclusion: Pretreatment with a loading dose of ticagrelor seems to be superior in reducing the incidence of percutaneous coronary intervention–related periprocedural myocardial infarction in Asian patients with acute coronary syndrome as compared with clopidogrel.

Original languageEnglish
JournalPerfusion (United Kingdom)
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • acute coronary syndrome
  • clopidogrel
  • percutaneous coronary intervention
  • periprocedural myocardial infarction
  • ticagrelor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Safety Research
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome'. Together they form a unique fingerprint.

  • Cite this

    Zhang, Y. R., Xue, Z. K., Chen, K. Y., Xu, L. X., Wang, W. D., Tao, H. Y., Liu, T., Che, J. J., Wang, X. W., Rha, S. W., Wang, J. R., & Wang, P. (Accepted/In press). Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome. Perfusion (United Kingdom). https://doi.org/10.1177/0267659120927857